Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1415-1422

  Yin, Chenxi ^a   Jiang, Chang ^a   Liao, Fangxin ^a   Rong, Yuming ^a   Cai, Xiuyu ^a   Guo, Guifang ^a   Qiu, Huijuan ^a   Chen, Xuxian ^a   Zhang, Bei ^a   He, Wenzhuo ^a   Xia, Liangping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Lactate dehydrogenase; PFS; Progression free survival

Indexed keywords

BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; SURVIVAL PREDICTION; SURVIVAL TIME; VERY ELDERLY; YOUNG ADULT;

EID: 84907376447     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S64559     Document Type: Article

References (39)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
2. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013-2019.
3. Giantonio BJ, Catalano PJ, Meropol NJ, et al; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539-1544.
4. Bennouna J, Sastre J, Arnold D, et al; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29-37.
5. Guan ZZ, Xu JM, Luo RC, et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer. 2011;30(10): 682-689.
6. Rugo HS. Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning? J Clin Oncol. 2012;30(9):898-901.
7. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(20):3239-3247.
8. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252-1260.
9. Sasich LD, Sukkari SR. The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). Saudi Pharm J. 2012;20(4):381-385.
10. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7(9): 987-989.
11. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891-899.
12. Busk M, Horsman MR. Relevance of hypoxia in radiation oncology: pathophysiology, tumor biology and implications for treatment. Q J Nucl Med Mol Imaging. 2013;57(3):219-234.
13. Anastasiou D, Poulogiannis G, Asara JM, et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science. 2011;334(6060):1278-1283.
14. Kostakis ID, Vaiopoulos AG, Philippou A, Papavassiliou AG, Koutsilieris M, Kouraklis G. Preoperative serum lactate dehydrogenase levels in colorectal and gastric cancer: a hospital-based case-control study. Biomark Med. 2013;7(1):131-137.
15. Kayser G, Kassem A, Sienel W, et al. Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol. 2010;5:22.
16. Agarwala SS, Keilholz U, Gilles E, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer. 2009;45(10):1807-1814.
17. Wang ZY, Loo TY, Shen JG, et al. LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis. Breast Cancer Res Treat. 2012;131(3):791-800.
18. Danner BC, Didilis VN, Wiemeyer S, et al. Long-term survival is linked to serum LDH and partly to tumour LDH-5 in NSCLC. Anticancer Res. 2010;30(4):1347-1351.
19. Hong J, Yoon HH, Ahn HK, et al. Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma. Acta Haematol. 2013;130(4):305-311.
20. Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol. 2012;30(27):3402-3407.
21. Abaza H, Ghanem A, Jmal A, et al. [Importance of determination of C reactive protein (CRP), carcinoembryonic antigen (CEA) and lactic dehydrogenase (LDH) in colorectal cancer]. Tunis Med. 2010;88(6):409-413. French.
22. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res. 2011;17(14):4892-4900.
23. Scartozzi M, Giampieri R, Maccaroni E, et al. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumabbased therapy in metastatic colorectal cancer patients. Br J Cancer. 2012;106(5):799-804.
24. Hecht JR, Trarbach T, Hainsworth JD, et al. Randomized, placebocontrolled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol. 2011;29(15):1997-2003.
25. Van Cutsem E, Bajetta E, Valle J, et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol. 2011;29(15):2004-2010.
26. Zhang B, He W, Zhou F, Guo G, Jiang C, et al. A Potential Administration-time Dependent Effect of Bevacizumab in Improving Overall Survival and Increasing Metastasis in Metastatic Colorectal Cancer. Chemotherapy. 2013;2:108.
27. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539-1544.
28. Li G, Gao J, Tao YL, et al. Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma. Chin J Cancer. 2012;31(4):197-206.
29. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association With survival and Activated Vascular Endothelial Growth Factor Pathway-A Report of the Tumour Angiogenesis Research Group. J Clin Oncol. 2006;24:4301-4308.
30. Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, Holdenrieder S. Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy. BMC Cancer. 2012;12:5.
31. Zhang B, He W, Zhou F, et al. A potential administration-time dependent effect of Bevacizumab in improving overall survival and increasing metastasis in metastatic colorectal cancer. 2013;2(1):1-5.
32. Wu Q, Shi Y, Chen L, Xiao X, Dai G. Effect and safety of bevacizumabcontaining chemotherapy treatment in Chinese patients with metastatic colorectal cancer. Onco Targets Ther. 2013;6:485-490.
33. Kim Y, Stolarska MA, Othmer HG. The role of the microenvironment in tumor growth and invasion. Prog Biophys Mol Biol. 2011;106(2): 353-379.
34. Folkman J. Tumor angiogenesis: role in regulation of tumor growth. Symp Soc Dev Biol. 1974;30(0):43-52.
35. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008;452(7184):181-186.
36. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.
37. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol. 2009;92(3):329-333.
38. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009;361:947-957
39. Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol. 2007;62(1):53-61.